Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.77 |
| ▸ | CNR1 | P21554 | 1/20 | 0.77 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.77 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.77 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20696605 | 0.93 | LMNA (0.64) | LMNACNR1ADRA1ATDP1KDM4E | |
| Ethambutol SCHEMBL3399 | 0.88 | LMNA (1.00) | LMNACNR1ADRA1ATDP1KDM4E | |
| Ethambutol SCHEMBL4029 | 0.88 | LMNA (1.00) | LMNACNR1ADRA1ATDP1KDM4E | |
| Ethambutol SCHEMBL2961583 | 0.88 | LMNA (1.00) | LMNACNR1ADRA1ATDP1KDM4E | |
| Ethambutol SCHEMBL2636850 | 0.88 | LMNA (1.00) | LMNACNR1ADRA1ATDP1KDM4E | |
| Ethambutol SCHEMBL9906602 | 0.88 | LMNA (1.00) | LMNACNR1ADRA1ATDP1KDM4E | |
| Ethambutol SCHEMBL15479016 | 0.88 | LMNA (1.00) | LMNACNR1ADRA1ATDP1KDM4E | |
| Ethambutol SCHEMBL3026481 | 0.85 | ABCC3 (1.00) | LMNACNR1ADRA1ATDP1KDM4E | |
| Ethambutol SCHEMBL3398 | 0.85 | ABCC3 (1.00) | LMNACNR1ADRA1ATDP1KDM4E | |
| Ethambutol SCHEMBL650049 | 0.85 | ABCC3 (1.00) | LMNACNR1ADRA1ATDP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170333427-A1 | MULTI-DRUG THERAPIES FOR TUBERCULOSIS TREATMENT | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170333427-A1 | MULTI-DRUG THERAPIES FOR TUBERCULOSIS TREATMENT | FNTB, DHFR, HMGCR | LMNA 3701/4885CNR1 2808/4885ADRA1A 850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.